Close menu




Biotechnology

Photo credits: pixabay.com

Commented by Stefan Feulner on July 11th, 2022 | 15:33 CEST

Easing at BioNTech and BASF, and Almonty Industries with a clear signal

  • Tungsten
  • Biotechnology

Concerns about the onset of a global recession are increasing dramatically, as shown by the economic data published last week. As a result, almost all asset classes corrected, and the fluctuation range increased enormously. In addition to the stock markets, which have been in a correction for months, crypto and precious metals prices also fell sharply. Even the oil price, which has been booming due to the Russian sanctions, was dragged down. At current levels, however, attractive, anti-cyclical entry opportunities are emerging.

Read

Commented by Fabian Lorenz on July 7th, 2022 | 14:33 CEST

A big surprise at BioNTech, and what are Valneva and NervGen doing?

  • Biotechnology
  • research

Surprise at BioNTech: competitor CureVac sues the Mainz-based biotech company for alleged patent infringements. Specifically, the lawsuit concerns BioNTech's Corona vaccine, which is based on mRNA technology. CureVac founder Ingmar Hoerr, in turn, is considered the discoverer of this new vaccination technology. However, CureVac failed with the development of its own Corona vaccine. Valneva also had no luck with its Corona vaccine, but it seems to have an attractive product pipeline. Nevertheless, the euphoria over the entry of the US pharmaceutical group Pfizer has faded. The situation at NervGen is different: according to experts, NervGen could achieve its greatest success in decades with NVG-291 in the fight against Alzheimer's disease. Tomorrow, a capital increase is to be completed, and the share price will likely regain momentum.

Read

Commented by Stefan Feulner on July 6th, 2022 | 11:58 CEST

Rheinmetall and Hensoldt stumble, good opportunities in XPhyto and Deutsche Telekom

  • Defense
  • Biotechnology

As a result of the shockingly weak economic data from the eurozone, the euro fell to its lowest level in almost 20 years with an exchange rate of 1.028 against the US dollar and is currently not far from parity. This crash was followed by European equities, with the DAX recording a new low for the year. Even last week's high flyers, defense stocks, were hit hard with double-digit daily losses. Despite the current correction, there are attractive long-term, anti-cyclical entry opportunities in many sectors at current levels.

Read

Commented by Stefan Feulner on July 5th, 2022 | 11:14 CEST

Strong signs at BioNTech and Defence Therapeutics, and Valneva closes the gap!

  • Biotechnology

****Without question, the future belongs to biotechnology. The record-breaking development of vaccines, tests and drugs in the wake of the Corona pandemic, which broke out more than two years ago, showed how important this sector is for humanity. Biotechnology stocks are consolidating strongly despite being established as a critical future technology. The NASDAQ Biotech Index has lost about 40% since last summer, creating attractive entry opportunities for investors at a significantly reduced level.

Read

Commented by André Will-Laudien on June 30th, 2022 | 13:49 CEST

Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?

  • Biotechnology

Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?

Read

Commented by Stefan Feulner on June 27th, 2022 | 12:12 CEST

BrainChip and Palantir with strong rebound - How does BioNTech react?

  • chips
  • Technology
  • Biotechnology

The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.

Read

Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST

Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?

  • Biotechnology
  • Pharma

Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.

Read

Commented by Nico Popp on June 22nd, 2022 | 13:01 CEST

Crisis investments? Pharmaceutical stocks in check: Bayer, XPhyto, Pfizer

  • Biotechnology
  • Pharma

Many investors want solid foundations for their portfolios when the market is in turmoil. Pharmaceutical stocks have always been considered largely detached from the overall market - after all, our health is not subject to market cycles. We explain whether this assumption is correct and how investors can now invest in stocks from the sector, using three shares as examples.

Read

Commented by Nico Popp on June 22nd, 2022 | 12:32 CEST

Market-independent returns? This is how it's done! Valneva, NervGen, BioNTech

  • Biotechnology

When the stock market is in high gear, it is time for cool heads. Even if many managers are suspected of only having an eye on the next few quarters, there are still some decisions with far-reaching consequences, especially in the case of takeovers and mergers. Most recently, Pfizer acquired a stake in the vaccine manufacturer Valneva. The share price performance to date did not suggest such a step. Here is why the decision could still pay off for shareholders and what signal effect the deal will have.

Read

Commented by Armin Schulz on June 17th, 2022 | 10:45 CEST

BioNTech, Defence Therapeutics, Formycon - Biotech stocks with a lot of future potential

  • Biotechnology

A look at the NASDAQ Biotechnology Index shows that the big hype on biotech companies seems to be over for now. Since September 2021, the index has been falling, repeatedly marking new lows. However, this decline can also be seen as an opportunity because the long-term prospects for the industry are good. People are getting older, and with age comes the diseases that want to be fought. Today we look at three companies with a lot of potential for the future.

Read